Source study found

Story checked

Targeted drug combination extends survival in advanced kidney cancer (opens in a new tab)

news-medical.net · 2026-10-28

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

2 claims go further than the study. 3 other points were not covered by the paper.

1 supported
2 overstated
3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

Targeted drug combination extends survival in advanced kidney cancer

news-medical.net · 2026-10-28

The story’s checkable claims.

Read the original story

NewsLink checks it

Mostly not supported

Two of six claims overstate the study. One of six checks out. Three claims the study doesn't address.

1 supported
2 overstated
3 not covered

Open claim evidence

The source study

Pazopanib alternating with bevacizumab in patients with metastatic clear-cell renal cell carcinoma naive to treatment: a multicentre, single-arm, phase 1/2 trial

The Lancet. Oncology · 2026

Open source record Open in Tessa

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6OverstatedResults of a phase 1/2 trial led by Roswell Park Comprehensive Cancer Center show that combining the targeted therapies bevacizumab (Avastin) and pazopanib (Votrient) significantly extends both progression-free and overall survival in patients with the most common type of kidney cancer.View evidenceHide evidence

As statedsignificantly extends both progression-free and overall survival

Why this verdict

The abstract-level profile supports a single-arm phase 2 finding of median PFS of 24.8 months after long follow-up and describes the regimen as showing promising antitumour activity. It does not support a headline-level causal claim that the combination 'significantly extends' PFS or overall survival, because there was no randomized comparator in the profiled evidence, and overall survival results are not present in the supplied abstract profile. The headline therefore outruns what the paper profile can substantiate.

Study evidence

In the phase 2 cohort (treatment‑naive metastatic clear‑cell RCC), median progression‑free survival was 24.8 months (95% CI 17.2–34.3) after a median follow‑up of 63.7 months.median PFS 24.8 months (95% CI 17.2–34.3)

Claim 2 of 6OverstatedThe regimen of pazopanib alternating with bevacizumab was found to be safe and efficacious in untreated patients with advanced clear cell kidney cancer, and was reasonably well-tolerated.View evidenceHide evidence

As statedsafe and efficacious; reasonably well-tolerated

Why this verdict

The paper profile supports that the regimen had an established RP2D, showed promising antitumour activity in a single-arm phase 2 cohort, and had described safety/tolerability findings with no treatment-related deaths. But the story's unhedged wording that it was 'safe and efficacious' is stronger than the abstract-level evidence, especially given the single-arm, non-randomized design and the profile's framing of efficacy as activity requiring phase 3 randomized confirmation.

Study evidence

The phase 1 portion established the RP2D for the alternating pazopanib–bevacizumab regimen.

Study evidence

Claim 3 of 6Not coveredThe strongest benefit was seen in favorable-risk patients, who made up the majority of the 51 patients enrolled in the nationwide clinical trial conducted at five academic cancer centers.View evidenceHide evidence

As statedstrongest benefit; majority of the 51 patients

Why this verdict

The profile supports that the trial was multicentre, conducted at five US academic cancer centres, and that the phase 2 activity-evaluable set was 51 patients, with the population predominantly favourable-risk. However, the supplied abstract profile does not report a favourable-risk subgroup efficacy result or establish that the 'strongest benefit' was in favourable-risk patients. It also indicates 53 phase 2 patients were enrolled and 51 were evaluable for activity, so the story's wording that 51 were enrolled is imprecise relative to the profile.

Study evidence

Claim 4 of 6Not coveredAmong the 51 patients in the phase 2 portion, median progression-free survival was 24.8 months and median overall survival was 63.2 months after a median follow-up of 63.7 months; in favorable-risk patients, PFS was 28.5 months and OS was 76.9 months.View evidenceHide evidence

As statedPFS 24.8 months, OS 63.2 months; favorable-risk PFS 28.5 months, OS 76.9 months

Why this verdict

The supplied profile supports the phase 2 median PFS of 24.8 months after median follow-up of 63.7 months in 51 activity-evaluable patients. It does not provide the overall survival value of 63.2 months or the favourable-risk subgroup PFS and OS values stated in the story. Those parts cannot be verified from the abstract-depth profile.

Study evidence

Claim 5 of 6Not coveredThe researchers believe this is the first clinical trial in kidney cancer to demonstrate both safety and efficacy using a combination of two VEGF-blocking drugs.View evidenceHide evidence

As statedfirst clinical trial in kidney cancer to demonstrate both safety and efficacy

Why this verdict

The profile supports that the regimen was novel and that the study evaluated dose, safety, and antitumour activity of alternating two VEGF-pathway agents. But the supplied abstract-level profile does not establish the historical claim that this was the first kidney-cancer clinical trial to demonstrate both safety and efficacy using two VEGF-blocking drugs.

Study evidence

The phase 1 portion established the RP2D for the alternating pazopanib–bevacizumab regimen.

Study evidence

Claim 6 of 6SupportedHigh blood pressure and elevated liver enzymes were the most common serious side effects.View evidenceHide evidence

As statedmost common serious side effects

Why this verdict

The profile reports that the most common grade 3–4 treatment-related adverse events in the pooled safety population were hypertension and elevated liver enzymes, specifically ALT and AST elevations. The story's lay phrasing as serious side effects is consistent with the reported grade 3–4 adverse-event findings.

Study evidence

Grade 3–4 treatment-related adverse events were reported in the pooled safety population; the most common were hypertension, elevated alanine aminotransferase (ALT), and elevated aspartate aminotransferase (AST).Hypertension 20/59 (34%); ALT elevation 10/59 (17%); AST elevation 7/59 (12%)

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

The phase 2 activity analysis used a per-protocol/evaluable population: 53 patients were enrolled in phase 2, 51 were evaluable for activity, and the evaluable set included six patients carried from phase 1.
The story refers to 51 patients as enrolled, but the profile distinguishes 53 enrolled from 51 evaluable for activity and notes the inclusion of six phase 1 patients in the activity-evaluable set. This analysis-population detail is not reflected and matters for interpreting the efficacy numbers.
From single-arm phase 2 interventional oncology trial
The authors note that phase 3 randomized data are needed to confirm the findings.
The profile identifies the lack of randomized comparator evidence and the need for phase 3 confirmation. The story caveats mention the trial was single-arm, but the supplied presentation does not reflect the authors' explicit need for randomized confirmatory data, which is important given the headline's causal framing.
From single-arm phase 2 interventional oncology trial
The phase 2 population was predominantly favourable-risk and predominantly White, which limits generalizability to other risk groups and populations.
The story reflects that favourable-risk patients made up the majority and emphasizes favourable-risk results, but it does not reflect the demographic skew noted in the profile, particularly the predominantly White study population, or its implications for generalizability.
From single-arm phase 2 interventional oncology trial; Pooled safety analysis (all treated patients across phase 1 and phase

5 things the story did carry across

Phase 1 dose-escalation established the recommended phase 2 dose of pazopanib 800 mg daily on days 1–28 plus bevacizumab 10 mg/kg on days 36 and 50 of a 10-week cycle.
The phase 2 efficacy evidence was from a multicentre, single-arm, non-randomized trial in treatment-naive metastatic clear-cell renal cell carcinoma, with PFS as the primary endpoint.
The main efficacy result in the abstract profile is median PFS of 24.8 months, framed as promising antitumour activity rather than definitive proof of survival extension.
Safety was assessed in all treated patients, with the most common grade 3–4 treatment-related adverse events being hypertension, elevated ALT, and elevated AST; five patients discontinued for drug-related serious adverse events and no treatment-related deaths occurred.
Important limitations include small/modest sample size and single-arm design without a concurrent comparator, limiting causal inference and precision.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoEstimate antitumour activity of the alternating pazopanib–bevacizumab regimen in treatment-naive metastatic clear-cell renal cell carcinoma, primarily via centrally assessed progression-free survival (phase 2).single-arm phase 2 interventional oncology trialExpand

In plain English

Single-arm, multicentre phase 2 evaluation of an alternating pazopanib (TKI) and bevacizumab regimen in treatment‑naive metastatic clear‑cell renal cell carcinoma, with primary efficacy endpoint median progression‑free survival (PFS) assessed by a masked central statistician review. Phase 2 enrolled 53 patients (51 evaluable for activity, including six carried from phase 1); after median follow‑up 63.7 months median PFS was 24.8 months (95% CI 17.2–34.3).

Key findings

In the phase 2 cohort (treatment‑naive metastatic clear‑cell RCC), median progression‑free survival was 24.8 months (95% CI 17.2–34.3) after a median follow‑up of 63.7 months.median PFS 24.8 months (95% CI 17.2–34.3)

What this piece can’t prove

Single‑arm phase 2 study without randomized comparator (reported in abstract).
Per‑protocol activity analysis (after one full 10‑week cycle) may select for patients who tolerate/complete initial treatment cycles.
Phase 2 activity evaluable set included six patients from phase 1 (as reported), potentially affecting the strictly 'phase 2 only' population definition.

1 further detail could not be confirmed from the summary.

2human in vivoEstablish the recommended phase 2 dose (RP2D) and characterize dose-limiting toxicity/safety of an alternating pazopanib–bevacizumab regimen in metastatic clear-cell renal cell carcinoma (phase 1).Phase 1 dose-escalation/selectionExpand

In plain English

Phase 1 dose-escalation portion of a multicentre single-arm trial tested four planned dose combinations of pazopanib (600 or 800 mg daily, days 1–28, followed by 7-day break) alternating with bevacizumab (5, 7.5, or 10 mg/kg given on days 36 and 50) on a 10-week cycle to identify a recommended phase 2 dose (RP2D) using an extended 15-week dose-limiting toxicity (DLT) assessment window. 25 patients were enrolled in phase 1, 18 were evaluable for DLTs during the extended 15-week safety assessment, and the RP2D was established as pazopanib 800 mg daily (days 1–28) with bevacizumab 10 mg/kg on days 36 and 50 of a 10-week cycle.

Key findings

The phase 1 portion established the RP2D for the alternating pazopanib–bevacizumab regimen.
Dose selection concluded with pazopanib 800 mg daily (days 1–28) plus bevacizumab 10 mg/kg on days 36 and 50 of a 10-week cycle as the RP2D.

What this piece can’t prove

Small phase 1 sample size (25 enrolled; 18 DLT-evaluable) limits precision in estimating DLT rates and tolerability.
Single-arm, non-randomised dose-finding design without a concurrent comparator arm.
Abstract does not report detailed DLT event types or counts for the phase 1 cohort in the text provided.
Phase 1 allowed up to one prior therapy in some patients, introducing heterogeneity in prior treatment exposure.

3human in vivoDescribe overall safety/tolerability of the regimen across treated patients (adverse events, serious adverse events, discontinuations).Pooled safety analysis (all treated patients across phase 1 and phase 2)Expand

In plain English

Pooled safety analysis of all treated patients (safety population n=59) showed grade 3–4 treatment-related adverse events with the most frequent being hypertension (20/59, 34%), alanine aminotransferase elevation (10/59, 17%), and aspartate aminotransferase elevation (7/59, 12%). Five patients (8%) discontinued for drug-related serious adverse events. No treatment-related deaths were reported.

Key findings

Grade 3–4 treatment-related adverse events were reported in the pooled safety population; the most common were hypertension, elevated alanine aminotransferase (ALT), and elevated aspartate aminotransferase (AST).Hypertension 20/59 (34%); ALT elevation 10/59 (17%); AST elevation 7/59 (12%)
Discontinuations due to drug-related serious adverse events occurred in a minority of patients.5/59 (8%) discontinued for drug-related serious adverse events

What this piece can’t prove

The pooled safety population is modest in size (n=59), limiting precision for less common adverse events.
Demographic skew in the reported population (94% White in phase 2) may limit generalizability of safety findings.
The abstract does not present a complete list of serious adverse events or laboratory/trend data beyond the reported common grade 3–4 events.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer